A strategic research collaboration and licence option agreement has been signed between Exscientia and Sanofi in the area of metabolic disease, such as diabetes. Exscientia will apply its unique platform to identify and validate combinations of drug targets that could work synergistically.  Starting with over a thousand disease-relevant target combinations, Exscientia will prioritise those opportunities with promising bispecific binding potential. Rapid delivery of multiple bispecific targets will be empowered by a pipeline of Exscientia capabilities driven by artificial intelligence and enabled automated design.